Werner H M J, Franke H R, Vermes I
Departments of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, Enschede, The Netherlands.
Climacteric. 2005 Sep;8(3):294-9. doi: 10.1080/13697130500197526.
Selective estrogen receptor modulators (SERMs) decrease the risk of developing breast cancer. As an antagonistic effect, SERMs may aggravate or induce climacteric symptoms. Hormone therapy (HT) would be able to alleviate these symptoms. The present in vitro study tries to elucidate the effects of several HT preparations combined with SERMs on estrogen receptor-positive (ER +) (i.e. MCF-7 and T-47D) and -negative (ER-) (i.e. MDA-MB-231) human breast cancer cells in vitro.
We performed experiments with various HT preparations (estradiol (E2)/E2 + progesterone/E2 + dihydrodydrogesterone /E2 + norethisterone acetate/E2 + medroxyprogesterone acetate/tibolone) in the concentration of 10(-6) mol/l together with SERMs (raloxifene or tamoxifen) added to different breast cancer cell lines in vitro. After an incubation period of 144 h, proliferation and apoptosis were measured. The first was measured by quantification of the expression of cyclin D1 mRNA, the latter by the Nicoletti method.
This in vitro study clearly demonstrates differences in results if various HT preparations, combined with SERMs, are added to ER + and ER- breast cancer cell lines.
Adding estradiol/progestogens in combination with a SERM to estrogen receptor-positive breast cancer cell lines does not obligatorily lead to proliferation of tumor cells. Not all progestogens act equally.
选择性雌激素受体调节剂（SERM）可降低患乳腺癌的风险。作为一种拮抗作用，SERM可能会加重或诱发更年期症状。激素疗法（HT）能够缓解这些症状。本体外研究试图阐明几种HT制剂与SERM联合应用对雌激素受体阳性（ER+）（即MCF-7和T-47D）和阴性（ER-）（即MDA-MB-231）人乳腺癌细胞的体外作用。
我们使用浓度为10（-6）mol/l的各种HT制剂（雌二醇（E2）/E2+孕酮/E2+二氢孕酮/E2+醋酸炔诺酮/E2+醋酸甲羟孕酮/替勃龙）与SERM（雷洛昔芬或他莫昔芬）一起添加到不同的体外乳腺癌细胞系中进行实验。孵育144小时后，测量细胞增殖和凋亡情况。前者通过定量细胞周期蛋白D1 mRNA的表达来测量，后者通过尼科莱蒂法测量。
本体外研究清楚地表明，将各种HT制剂与SERM联合添加到ER+和ER-乳腺癌细胞系中，结果存在差异。
将雌二醇/孕激素与SERM联合添加到雌激素受体阳性乳腺癌细胞系中不一定会导致肿瘤细胞增殖。并非所有孕激素的作用都相同。
